Skip to content

Study · Non-randomized trial · n = 40 · 2000

3 results

Addition of GnRH antagonist in cycles of poor responders undergoing IVF.

Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M

Human reproduction (Oxford, England)1 Oct 2000Cited by 63 (Europe PMC)

PMID11006188 (opens in a new tab)DOI10.1093/humrep/15.10.2145 (opens in a new tab)PepBankPUB-11006188
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In poor responders undergoing IVF, cancellation, gonadotrophin use, mature oocytes, HCG-day oestradiol, fertilization and transferred embryos did not differ significantly with added cetrorelix.

    In plain wordsIn poor responders undergoing IVF, stimulation and IVF outcomes did not differ significantly with added cetrorelix versus stimulation alone.

    Peptide
    Cetrorelix
    Outcome
    No significant changeStimulation and IVF outcomes
    Study

    n = 40

    Comparator
    Ovarian stimulation without GnRH agonist or antagonist
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg daily · late follicular phaseAs given in this study (human).

    Source sentences

    Summary
    There was no statistically significant difference between the groups
    3 context sentences
    Summary · context
    cancellation rate, number of ampoules of gonadotrophin used, number of mature oocytes retrieved, oestradiol concentrations on the day of injection of human chorionic gonadotrophin (HCG), fertilization rate and number of embryos transferred.
    Summary · context
    In this study, we compared two ovarian stimulation protocols in which no GnRH agonists were used.
    Summary · context
    while group II (n = 20) patients received ovarian stimulation for 20 cycles, including the administration of a GnRH antagonist (Cetrorelix, 0.25 mg daily) during the late follicular phase.
  2. 02HumanNon-randomized trialEfficacy outcome

    In poor responders undergoing IVF, clinical pregnancy rates were 20% with added cetrorelix versus 6.25% without it, without a significant difference.

    In plain wordsIn poor responders undergoing IVF, clinical pregnancy rates did not differ significantly with added cetrorelix versus stimulation alone.

    Peptide
    Cetrorelix
    Outcome
    No significant changeClinical pregnancy rate
    Study

    n: not reported in source

    Comparator
    Ovarian stimulation without GnRH agonist or antagonist
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg daily · late follicular phaseAs given in this study (human).

    Measurements

    Clinical pregnancy rate
    20%
    Cetrorelix group (group II)
    Clinical pregnancy rate
    6.25%
    No GnRH analogue (group I)

    Source sentences

    Summary
    The clinical pregnancy and implantation rates in group II appeared higher than in group I, but were not significantly different (20 and 13.33% compared with 6.25 and 3.44% respectively).
    1 context sentence
    Summary · context
    while group II (n = 20) patients received ovarian stimulation for 20 cycles, including the administration of a GnRH antagonist (Cetrorelix, 0.25 mg daily) during the late follicular phase.
  3. 03HumanNon-randomized trialEfficacy outcome

    In poor responders undergoing IVF, implantation rates were 13.33% with added cetrorelix versus 3.44% without it, without a significant difference.

    In plain wordsIn poor responders undergoing IVF, implantation rates did not differ significantly with added cetrorelix versus stimulation alone.

    Peptide
    Cetrorelix
    Outcome
    No significant changeImplantation rate
    Study

    n: not reported in source

    Comparator
    Ovarian stimulation without GnRH agonist or antagonist
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg daily · late follicular phaseAs given in this study (human).

    Measurements

    Implantation rate
    13.33%
    Cetrorelix group (group II)
    Implantation rate
    3.44%
    No GnRH analogue (group I)

    Source sentences

    Summary
    The clinical pregnancy and implantation rates in group II appeared higher than in group I, but were not significantly different (20 and 13.33% compared with 6.25 and 3.44% respectively).
    1 context sentence
    Summary · context
    while group II (n = 20) patients received ovarian stimulation for 20 cycles, including the administration of a GnRH antagonist (Cetrorelix, 0.25 mg daily) during the late follicular phase.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.